Pancreatic and Hepatic Oncology Research

The paper fine-maps a PDAC GWAS signal at chr1p36.33 and identifies KLHL17 as a target gene regulated by JunB/D, with potential implications for inflammation and PDAC risk.

This study shows that mutant GNAS drives a gastric metaplasia gene signature and glycolytic dependency in IPMNs, offering a therapeutic target.

This study evaluates combinations of PDAC biomarkers across multiple labs, finding improved sensitivity and specificity for early-stage detection compared to CA19-9 alone.

This study investigates how drug-resistant pancreatic cancer cells alter biophysical interactions with stromal fibroblasts in 3D co-culture models using imaging and RNA-seq analysis.

This study identifies ADRA2A as a gene that promotes the classical/progenitor subtype and reduces aggressiveness in pancreatic cancer by altering transcriptome and metabolome profiles.

The paper profiles the immune microenvironment of PanINs in 3D at single-cell resolution to understand inflammation's role in cancer progression and finds immune heterogeneity and correlations with PanIN grade.

This study identifies SPP1+ macrophages and CTHRC1+ fibroblasts as synergistic contributors to an immunosuppressive tumor microenvironment in PDAC, linked to poor prognosis.

The paper uses AI-based 3D tissue mapping to show PanIN lesion sizes follow a power-law distribution and identifies growth mechanisms driving pancreatic cancer precursor lesions.

This study identifies ROR2 as a regulator of cellular plasticity in pancreatic neoplasia, showing it promotes an aggressive PDAC phenotype and resistance to KRAS inhibitors.

This study shows IMP1 promotes early pancreatic cancer progression by altering the transcriptomic landscape and enhancing metastasis in mouse models.

This study shows that stabilizing wild-type p53 with Nutlin-3a reduces ADM and PanIN formation in a KrasG12D mouse model by promoting acinar cell differentiation.

This paper identifies NGL-1 as a stromal immunomodulator in pancreatic cancer that promotes tumor growth by modulating the tumor microenvironment through TGF-β and transcription factor pathways.

This study shows that combining FOLFIRINOX with stereotactic body radiotherapy remodels pancreatic ductal adenocarcinoma, improving stromal and metabolic features and prognosis.

This study compares scRNA-seq of unenriched and CAF-enriched samples from PDAC tumors, finding that CAF enrichment better captures heterogeneity but loses other TME cells.

This study evaluates the therapeutic potential of RMC-7977, a broad-spectrum RAS inhibitor, in pancreatic ductal adenocarcinoma models, showing strong anti-tumor effects with minimal impact on normal tissues.

This study identifies a distinctive PDAC niche in pancreatic lobules characterized by nascent stroma and classical tumor cell phenotype, highlighting the role of acinar-to-ductal metaplasia and microenvironmental factors in tumor progression.

This study identifies GNASR201C as a driver of pyloric metaplasia in IPMN, characterized by tumor-suppressive glycans that inhibit cancer progression.

This study shows that pulsed low-dose-rate radiation combined with chemotherapy shifts pancreatic cancer-associated fibroblasts from tumor-promoting to tumor-suppressing, reducing desmoplasia and improving neoadjuvant therapy.

This study shows that combining gemcitabine with CXCR4 inhibitors and anti-PD1 therapy improves immune response and survival in pancreatic cancer models.

This study identifies RCC1 as a novel therapeutic target in PDAC, showing its role in tumor progression and drug resistance through the c-Myc-RCC1-Ran axis.

This study identifies TLR2 as a target to counteract adaptation to ARF6 depletion in KRAS-driven PDAC, reducing proliferation, migration, and invasion.

This study shows neoadjuvant therapy in PDAC increases complement gene expression in the tumor microenvironment, linked to better survival and reduced immune exhaustion.

This study identifies differentially co-expressed head-to-head gene pairs in pancreatic cancer and highlights key regulators and potential biomarkers.

This study compares molecular features of young-onset and average-onset pancreatic cancer using multi-omic data, finding distinct mutation patterns and immune profiles with prognostic implications.

The paper develops an AI-derived prognostic signature for pancreatic cancer using multi-center cohorts and machine learning, showing improved predictive performance and clinical relevance.

This study evaluates three PDAC molecular signatures across eight datasets, finding inconsistent subtyping and low classification accuracy, suggesting technical biases and the need for multi-omic approaches.

The paper identifies differentially expressed genes and modules associated with long-term survival in PDAC patients using integrative transcriptome analysis.

This study develops a prognostic model for pancreatic cancer using pyroptosis-related genes, identifying key genes and showing differences in risk groups.